Login / Signup

Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.

Germana BanconeGornpan GornsawunCindy S ChuPen PornSampa PalPooja BansilGonzalo J DomingoFrancois H Nosten
Published in: PloS one (2018)
The Carestart G6PD biosensor represents a significant improvement for quantitative diagnosis of G6PD deficiency over previous versions. Further improvements and validation studies are required to assess its utility for informing radical cure decisions in malaria endemic settings.
Keyphrases
  • gold nanoparticles
  • sensitive detection
  • high resolution
  • quantum dots
  • label free
  • mass spectrometry
  • replacement therapy
  • clinical evaluation